Siemens Healthineers: Diagnostics Unit on the Block as Shares Plumb New Depths

German medtech giant Siemens Healthineers considers selling its diagnostics unit for €6 billion to counter a 52-week stock low, €14 billion debt, and headwinds from German austerity, US tariffs, and China weakness.

The German medtech giant is staring down a confluence of headwinds that have sent its stock to a 52-week low of €33.62 — a level just 3% above the year's trough. With the shares now trading roughly 22% below their 200-day moving average, the company is weighing a radical cure for what ails it: a potential €6 billion sale of its diagnostics division to private equity.

The Diagnostics Dilemma

Management is actively exploring a disposal of the diagnostics unit, which has long been a drag on group margins. First-quarter revenues in the division slipped around 3%, primarily due to weak demand from China. A sale would serve a dual purpose: shedding the lowest-margin business while chipping away at a debt pile of roughly €14 billion. The imaging and Varian cancer therapy segments would remain untouched. No final decision has been made — the company could yet opt to keep running the unit itself.

The potential €6 billion price tag would provide meaningful ammunition for deleveraging, though it would not fully extinguish the debt burden. That matters because Siemens AG, which still owns just over 67% of Healthineers, currently guarantees loans of up to €13.9 billion — a backstop that will eventually disappear.

A Delayed Break from the Parent

The spin-off from Siemens is taking longer than many investors had hoped. The parent company plans to put the separation to a vote at the ordinary annual general meeting in February 2027, rather than calling an extraordinary meeting in the first half of 2026 as some had anticipated. Under the plan, Siemens would transfer 30% of its stake directly to its own shareholders, relinquishing majority control.

That timeline pushes the full independence of Healthineers nearly a year beyond earlier expectations. Once completed, the company will need to refinance those €13.9 billion in guaranteed loans on its own — a task made more challenging by the current operational pressures.

Three Fronts, One Storm

The domestic market is delivering the first blow. Germany's cabinet approved a healthcare austerity package in late April that aims to save €20 billion by 2027, with more than 40% of the cuts hitting hospitals directly. Clinics are already delaying purchases of imaging systems and lab diagnostics — the very equipment that forms Healthineers' core business. The Hessen hospital association has warned of an impending wave of insolvencies, noting that two-thirds of German hospitals are already in the red.

Tariffs add a second layer of pain. New US duties are expected to weigh on adjusted EBIT by around €400 million this fiscal year, while unfavorable currency movements could cost another €200 million to €250 million. The company's China business, particularly in laboratory diagnostics, has already posted a slight revenue decline. For the second quarter, management expects revenue growth to fall short of its own 5% to 6% target range.

Bright Spots in the Pipeline

Not all is gloom. The Varian division has secured up to $60 million in funding from the US research agency ARPA-H to advance photon flash radiation therapy, with Healthineers contributing another $23 million of its own. In April, the company signed a clinical supply agreement with Radiopharm Theranostics to produce and distribute the PET imaging agent RAD101 through its US network, after the FDA granted the drug fast-track status.

These are genuine breakthroughs, but they operate in segments too small to offset weakness in the core business in the near term.

Analyst Optimism — With a Caveat

Despite the stock's 21% decline since the start of the year and a relative strength index of 28.6 (deep in oversold territory), the analyst community sees substantial upside. The consensus price target stands at roughly €54 — more than 50% above the current level of €35.05. The logic: a fully independent company with broader free float would attract a wider investor base.

All eyes now turn to May 7, when Healthineers reports detailed second-quarter results. Management will have the chance to demonstrate how the three headwinds — domestic austerity, tariffs, and China weakness — are truly interacting, and whether the full-year guidance of 5% to 6% revenue growth remains credible. Investors will also be listening closely for any official acknowledgment of the diagnostics sale talks.